It focuses on nine major priority areas, namely: Leadership and Governance for Health; Health Service Delivery; Human Resources for Health; Health Financing; Health Information Systems; Health Technologies; Community Ownership and Participation; Partnerships for Health Development; and Researc...h for Health.
more
The Guide has been developed to enhance the knowledge capabilities of NDMAs and their local partners. This is accomplished by exposing them to the existing tools and services developed by the international community to facilitate effective disaster response to any scale of disaster (small, medium an...d large) and assist in comprehensive response preparedness
more
CAFOD Policy Briefing Paper
The 6th edition of the essential medicine list has been developed based on the 5th edition list of essential medicines, the National Standard Treatment Guidelines and Protocols 2013, list of laboratory commodities and List of Consumables used in public health facilities.
Section 1, Introduction to Men's Reproductive Health Services, Revised Edition, is designed to help sites and health care workers address organizational and attitudinal barriers that may exist when initiating, providing, or expanding a men's reproductive health services program. It also provides bas...ic information on a variety of reproductive health issues relevant to reproductive health services for men, including sexuality, gender, anatomy and physiology, contraception, and sexually transmitted infections.
more
This document is to guide policy makers, managers, districts, health workers, communities, NGOs and all other stakeholders on how to implement newborn health services.
Development of IEC materials for the NDoH launch of oral PrEP at selected sex worker sites in South Africa
HRH Strategy for the Health Sector: 2012/13 – 2016/17
How to do it best for the patient and the family
Global Fund Strategy 2023-2028
Available in different languages from the website https://www.theglobalfund.org/en/publications/
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...G ne soit pas apparue dans les populations naïves aux TAR incapables
de supprimer la charge virale dans les essais cliniques, certains éléments portent à croire que la résistance au
DTG peut émerger chez les personnes suivant des schémas thérapeutiques incluant le DTG. L’OMS recommande aux
pays qui étendent les TAR incluant le DTG d’accompagner ce déploiement d’une surveillance en routine de la pharmacorésistance
more